Skip to main content

Abstracts

2022

Budget Impact Analysis of Bimekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis in Greece

Koulentaki M, Tzanetakos C, Stratigos A, Sotiriou E, Ladha I, Kountouris V, Relakis J, Kourlaba G, Value in Health, 2022. Volume 25, Issue 12, S185. https://doi.org/10.1016/j.jval.2022.09.893

2022

Cost-Effectiveness Analysis of Bimekizumab in Patients With Moderate-to-Severe Plaque Psoriasis in Greece

Koulentaki M, Tzanetakos C, Stratigos A, Sotiriou E, Ladha I, Christou P, Relakis J, Kourlaba G, Value in Health, Volume 25, 2022. Issue 12, S74. https://doi.org/10.1016/j.jval.2022.09.358
2022

A Budget Impact Analysis of Introducing a New Combination of Atorvastatin and Ezetimibe in Greece

Koulentaki M, Gourzoulidis G, Chotzagiannoglou V, Beletsi A, Kourlaba G, Value in Health, 2022. Volume 25, Issue 12, S138. https://doi.org/10.1016/j.jval.2022.09.664
2022

Budget Impact Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, Beletsi A, Kourlaba G, Value in Health, Volume 25, Issue 1, S48. https://doi.org/10.1016/j.jval.2021.11.224
2022

Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece

Gourzoulidis G, Koulentaki M, Kattamis A, Bouzani M, Giatra C, Chotzagiannoglou V, Beletsi A, Kourlaba G, Value in Health, Volume 25, Issue 1, S101. https://doi.org/10.1016/j.jval.2021.11.481
2021

Application of Multicriteria Decision Analysis to Determine the Value of Prophylaxis Relative to On-Demand Treatment in Hemophilia A and Emicizumab versus Replacement Therapy in the Greek Healthcare Setting

Gourzoulidis G, Stefanou G, Economou M, Vakalopoulou S, Filippidis G, Soultatis G, Kontos D, Tzima S, Ntemousis F, Fassa A, Kourlaba G, Clin Drug Investig 2022 Jan;42(1):75-85. DOI: 10.1007/s40261-021-01108-4 . Epub 2021 Dec 7.
 
2020

Cost-Effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-Small-Cell-Lung Cancer in Greece

Gourzoulidis G, Zisimopoulou O, Boubouchairopoulou N, Michailidi C, Almond C, Tzanetakos C, et al. Value in Health. 2020;23:S442. https://doi.org/10.1016/j.jval.2020.08.244

2019

Does a standard Willingness-to-pay thereshold exist in Greece?

Tzanetakos C, Stefanou G, Gourzoulidis G. Value in Health. 2019;22:S772-S3. https://doi.org/10.1016/j.jval.2019.09.1963

2019

End-of-LIFE Cost for Lung Cancer Patients in Greece: A hospital-based retrospective study

Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S476. https://doi.org/10.1016/j.jval.2019.09.405

2019

Budget Impact Analysis of a Biosynthetic MESH for abdominal Wall Hernia repair in Complex Hernias in Greece

Vellopoulou K, Apostolidis S, Chatzimavroudis G, Chrisoheris P, Christodoulidis G, Ntatsis K, et al. Value in Health. 2019;22:S673. https://doi.org/10.1016/j.jval.2019.09.1436

2019

Real-World Data of Nivolumab in Non Small Cell Lung Cancer patients in Greece

Kourlaba G, Kokkotou E, Papaspiliou A, Stefanou G, Stournara L, Syrigos K. Value in Health. 2019;22:S435-S6. https://doi.org/10.1016/j.jval.2019.09.202

2019

Budget Impact Analysis of Damoctocog Alfa Pegol in Severe Hemophilia A in Greece

Vellopoulou K, Georgilis A, Byrne A, Gray E, De Meyer N, Kourlaba G. Value in Health. 2019;22:S844.

2019

Cost-effectiveness analysis of Tofacitinib for the treatment of moderate to severe active uclerative colitis in Greece

Vellopoulou K, Stefanou G, Tzanetakos C, Boubouchairopoulou N, Nakou M, Kourlaba G. Value in Health. 2019;22:S619-S20. https://doi.org/10.1016/j.jval.2019.09.1142

2019

Cost-minimization Analysis of Damoctocog Alfa Pegol in severe Hemophilia A in Greece

Vellopoulou K, Georgilis A, Byrne A, Gray E, De Meyer N, Kourlaba G Value in Health. 2019;22:S848. https://doi.org/10.1016/j.jval.2019.09.2371